NJ-DRIVEWEALTH
13.7.2022 15:02:09 CEST | Business Wire | Press release
DriveWealth, LLC , a global fintech investment rail and pioneer in fractional investing, today released its new DriveTrends study, “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty ,” a closer look at how the first prolonged bear market many investors have faced impacted trading behaviors of millions across APAC, EMEA, LATAM, and the U.S. during the first half of 2022. The study analyzes data of more than 12 million investors worldwide who trade shares of U.S. equities through DriveWealth’s network of 100+ global partners, including Block Inc.’s Cash App, Revolut, and Navy Federal Financial Group.
Even amid market lows, data shows trading remained popular among Millennials, a demographic that continues to demand more access to traditional and alternative investment products and tools. The report showcases how Millennials’ increasing preference for innovations like fractional equity trades and diversified portfolios have shaped a new market for digital wallet app users , which is anticipated to exceed 4.4 billion by 2025, according to Juniper Research .
“The ability for providers to offer fractionalized trading has provided a whole new segment of consumers with the opportunity to access wealth creating markets using the smartphones they already own,” said Harry Temkin , Chief Information Officer at DriveWealth. “Millennials are motivating fintechs and neobanks to innovate their product suite to improve access to U.S. equities and financial literacy tools in underserved markets. Our recent partnerships with companies like Toss Securities , Goalsetter , and Sproutfi are testaments to the amount of power Millennials have to shape the financial ecosystem at large – all they need is an investment button that’s now accessible in the palm of their hand.”
Based on data from the first half of 20221 , key takeaways from the report include:
- Millennials represented the largest proportion of new investment account openings worldwide at 46%. While data showed that almost half of Gen-Z investors opened their first account during the March 2020 to August 2021 period (representing a large and growing market share of investors), Gen-Z scaled back while Millennials took the lead this year. This could signal a potential influx of cash into investment platforms that meet their investing needs, as U.S. Millennial wealth has more than doubled from the fourth quarter of 2019 to the end of 2021.
- While ‘meme stocks’ and Reddit comments continued to inspire news headlines, the report shows global investors (especially younger ones) gravitated toward more tried-and-true names to create their portfolios. AAPL, TSLA, and AMZN continue to retain their position as the top three symbols traded worldwide.
-
Millennials represented both the highest average trades per account (19) worldwide and the largest proportion of trades in each region. This generation drove:
- 94% of trades in APAC
- 69% of trades in EMEA
- 53% of trades in LATAM
- 53% of trades in the U.S.
- Across the U.S., LATAM, and EMEA, approximately 96% of all activity was driven by fractionalized trades through DriveWealth’s platform. This is a measurable increase from the second half of 2020, where fractional trades drove 92% of global activity.
- The top two traded symbols among Millennials in APAC were TQQQ and SQQQ, triple-leveraged ETFs that track a Nasdaq 100 index ETF, QQQ. Known as a high-risk sector, this suggests Millennials in this region may be motivated by riskier investments with the potential for high returns.
“As we dive deeper into the Decade of the Digital Investor , we’re seeing a paradigm shift in investing,” said Gayathri Rajan , Chief Product Officer at DriveWealth. “Despite market uncertainty, people – especially younger investors – are still investing in the brands they love using digital tools that are making markets accessible and affordable for them. As a pioneer of fractional trading, we’re excited to continue working with our partners to develop even more ways for investors worldwide to access the markets through our API-based platform.”
To read the full results of “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty,” click here . For more information on DriveWealth’s full suite of services, see here .
About DriveWealth
DriveWealth , a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn .
1 DriveWealth proprietary data. All data has been rounded and reflects approximate figures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005508/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
